CMAB vs IMAB in Metastatic Prostate Cancer

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00255268
First received: October 26, 2005
Last updated: August 24, 2007
Last verified: August 2007

October 26, 2005
August 24, 2007
August 2004
Not Provided
Time to progression
Same as current
Complete list of historical versions of study NCT00255268 on ClinicalTrials.gov Archive Site
  • Safety
  • Quality of Life
Same as current
Not Provided
Not Provided
 
CMAB vs IMAB in Metastatic Prostate Cancer
Longitudinal, Randomized, Open and Prospective Clinical Trial to Evaluate the Efficacy of Continuous vs Intermittent Maximum Androgen Blockade (CMAB vs IMAB) With Goserelin-Bicalutamide Combination in the Treatment of Hormonal naïve With Metastatic Prostate Cancer

To evaluate the efficacy, safety and survival of two treatment regimens: Continuous Intermittent Maximum Androgen Blockade, using goserelin and bicalutamide in patients with prostate cancer. Primary endpoint is time to progression. Fifteen patients will be evaluated. QoL evaluation is also included.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Metastatic Prostate Cancer
  • Drug: Goserelin
  • Drug: Bicalutamide
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
15
Not Provided
Not Provided

Inclusion Criteria:

  • Histological diagnosis of D2 of Adenocarcinoma,
  • Naivety to treatment
  • Valuable bone metastasis

Exclusion Criteria:

  • Hematological, liver or renal toxicity Grade IV
  • Severe and active infections
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Mexico
 
NCT00255268
D6876L00010
Not Provided
Not Provided
AstraZeneca
Not Provided
Study Director: AstraZeneca Mexico Medical Director, MD AstraZeneca
AstraZeneca
August 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP